TP53基因组改变对接受CD19嵌合抗原受体T细胞治疗的大B细胞淋巴瘤的影响
研究纳入153例接受CD19-CAR-T治疗的复发或难治性大B细胞淋巴瘤成人患者,TP53改变常见(37%),与较差的完全缓解率和总生存率相关;1年OS在TP53改变组为44%,野生型为76%(P=0.012)。转录组分析提示TP53改变与CAR-T细胞毒性相关通路失调有关。
要点
- TP53改变在大B细胞淋巴瘤中常见(37%),与CD19-CAR-T治疗后较差的完全缓解和总生存相关。
- TP53改变组1年OS为44%,野生型为76%(P=0.012)。
- TP53改变与干扰素和死亡受体信号通路失调及CD8 T细胞肿瘤浸润减少相关。
核心结论
- TP53是有效的肿瘤内在生物标志物,可帮助接受CD19-CAR-T治疗的LBCL患者进行风险分层和临床试验设计。
- TP53的作用应在独立队列中进一步验证。
研究设计与样本
- 研究纳入153例接受CD19-CAR-T治疗的复发或难治性LBCL成人患者。
- 对部分患者的CAR-T前肿瘤样本进行靶向下一代测序。
- 在562例新诊断LBCL患者队列中进行基因组和转录组分析,研究细胞通路与TP53状态的相互作用。
主要发现
- 完全缓解率为54%,中位总生存期为21.1个月(95% CI,14.8至未达到),无进展生存期为6个月(3.4至9.7)。
- 组织学和细胞遗传学特征不能预测完全缓解。
- 在82例进行下一代测序的患者中,完全缓解率和总生存率与未测序队列相当。
- TP53改变(突变和/或拷贝数改变)常见(37%),在单变量和多变量回归模型中与较差的完全缓解率和总生存率相关。
- TP53改变组1年OS为44%(95% CI,29至67),野生型组为76%(65至89)(P=0.012)。
局限性
- TP53的作用应在独立队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 genomic alterations are detrimental to response outcomes in LBCL treated with CD19-CAR-T. MATERIALS AND METHODS: Patients with LBCL treated with CD19-CAR-T were included. Targeted next-generation sequencing was performed on pre-CAR-T tumor samples in a subset of patients. Response and survival rates by histologic, cytogenetic, and molecular features were assessed. Within a cohort of newly diagnosed LBCL with genomic and transcriptomic profiling, we studied interactions between cellular pathways and TP53 status. RESULTS: We included 153 adults with relapsed or refractory LBCL treated with CD19-CAR-T (axicabtagene ciloleucel [50%], tisagenlecleucel [32%], and lisocabtagene maraleucel [18%]). Outcomes echoed pivotal trials: complete response (CR) rate 54%, median overall survival (OS) 21.1 months (95% CI, 14.8 to not reached), and progression-free survival 6 months (3.4 to 9.7). Histologic and cytogenetic LBCL features were not predictive of CR. In a subset of 82 patients with next-generation sequencing profiling, CR and OS rates were comparable with the unsequenced cohort. TP53 alterations (mutations and/or copy number alterations) were common (37%) and associated with inferior CR and OS rates in univariable and multivariable regression models; the 1-year OS in TP53-altered LBCL was 44% (95% CI, 29 to 67) versus 76% (65 to 89) in wild-type (P = .012). Transcriptomic profiling from a separate cohort of patients with newly diagnosed lymphoma (n = 562) demonstrated that TP53 alterations are associated with dysregulation of pathways related to CAR-T-cell cytotoxicity, including interferon and death receptor signaling pathway and reduced CD8 T-cell tumor infiltration. CONCLUSION: TP53 is a potent tumor-intrinsic biomarker that can inform risk stratification and clinical trial design in patients with LBCL treated with CD19-CAR-T. The role of TP53 should be further validated in independent cohorts.
引用
- Shouval R, Alarcon Tomas A, Fein JA, et al. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2021. PMID: 34860572. doi:10.1200/JCO.21.02143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。